Latest news
Loading news…
NeoImmuneTech
ActiveOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 HighHeat score — how much recent activity & attention the company has (web traffic, news, hiring).📈 Low growthGrowth score — momentum trend across web traffic, headcount and other growth signals. Seongnam, Kyonggi-do, South Korea Founded 2014 51-100 employees For Profit
NeoImmuneTech is a biotech company developing T cell-centered novel immunotherapeutics.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
0
Monthly Visits
Available in Pro Contacts
29
Ticker
950220
KOSDAQ - Korean Securities Dealers Automated Quotations
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
IPO & Stock
- IPO status
- Public
- Ticker
- 950220
- Exchange
- KOSDAQ - Korean Securities Dealers Automated Quotations
- IPO date
- Mar 16, 2021
- Raised at IPO
- $104M
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Technology & IP
- Active technologies
- 13
Company Info
- Founded
- 2014
- Employees
- 51-100
- Operating status
- Active
- Company type
- For Profit
- Org types
- company
- Founders
- 1
- News articles
- 31
- HQ
- Seongnam, Kyonggi-do, South Korea
- Region
- Asia-Pacific (APAC)
- Exit date
- Mar 16, 2021
Signals & Scores
- Heat score
- High
- Growth score
- Low
- Trend (7d)
- 0
- Trend (30d)
- 0
- Trend (90d)
- -0.7
- Last leadership hire
- Apr 2, 2024
Key People at NeoImmuneTech
President and CEO
29
professional contacts at NeoImmuneTech
Contact execs at NeoImmuneTech →Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to NeoImmuneTech
Loading news…
FAQs about NeoImmuneTech
People who checked this page also checked these
Browse the full Acquirezy directory.